Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

On May 23, 2025, the FDA expanded the approval of MenQuadfi (Sanofi) to include infants aged 6 weeks to 23 months for the prevention of meningococcal disease. MenQuadfi is now the only quadrivalent ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Superior Financial Strength, High Growth Trend Stock Priced at High Valuations The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. Estimates data is ...

Sanofi India Limited, was initially incorporated as Aventis Pharma Limited in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.